These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30566415)

  • 1. Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia.
    Ivkovic J; Lindsten A; George V; Eriksson H; Hobart M
    J Clin Psychopharmacol; 2019; 39(1):13-19. PubMed ID: 30566415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder.
    Clayton AH; Ivkovic J; Chen D; George V; Hobart M
    J Clin Psychopharmacol; 2020; 40(6):560-567. PubMed ID: 33136923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
    Ishigooka J; Iwashita S; Tadori Y
    Psychiatry Clin Neurosci; 2018 Sep; 72(9):692-700. PubMed ID: 29774628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.
    Newcomer JW; Eriksson H; Zhang P; Weiller E; Weiss C
    Curr Med Res Opin; 2018 Dec; 34(12):2197-2205. PubMed ID: 29985680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.
    Gopal S; Lane R; Nuamah I; Copenhaver M; Singh J; Hough D; Bach M; Savitz A
    CNS Drugs; 2017 Sep; 31(9):797-808. PubMed ID: 28660406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
    Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
    Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
    Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
    Ishigooka J; Iwashita S; Tadori Y
    Psychiatry Clin Neurosci; 2018 Jun; 72(6):445-453. PubMed ID: 29582518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
    Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
    Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
    Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.
    Vieta E; Sachs G; Chang D; Hellsten J; Brewer C; Peters-Strickland T; Hefting N
    J Psychopharmacol; 2021 Aug; 35(8):971-982. PubMed ID: 33691517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
    Correll CU; He Y; Therrien F; MacKenzie E; Meehan SR; Weiss C; Hefting N; Hobart M
    J Clin Psychiatry; 2022 Mar; 83(2):. PubMed ID: 35235720
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.
    Correll CU; Shi L; Weiss C; Hobart M; Eramo A; Duffy RA; Weiller E; Baker RA
    CNS Spectr; 2019 Oct; 24(5):507-517. PubMed ID: 30306884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
    Newcomer JW; Eriksson H; Zhang P; Meehan SR; Weiss C
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31577867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
    Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
    Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.